	US 12,102,436 B2
	Electrophysiology catheter design
Mark T. Stewart, Lino Lakes, MN (US); Mark Allen Benscoter, Dellwood, MN (US); Jon Virgil Evans, Eden Prairie, MN (US); Timothy G. Laske, Shoreview, MN (US); and Gonzalo Martinez, Mendota Heights, MN (US)
Assigned to Medtronic Ablation Frontiers LLC, Minneapolis, MN (US)
Filed by Medtronic Ablation Frontiers LLC, Minneapolis, MN (US)
Filed on Feb. 11, 2021, as Appl. No. 17/173,230.
Application 17/173,230 is a division of application No. 16/039,919, filed on Jul. 19, 2018, granted, now 10,945,625.
Application 15/164,445 is a division of application No. 13/750,133, filed on Jan. 25, 2013, granted, now 9,370,311, issued on Jun. 21, 2016.
Application 16/039,919 is a continuation of application No. 15/164,445, filed on May 25, 2016, granted, now 10,039,467, issued on Aug. 27, 2018.
Claims priority of provisional application 61/727,163, filed on Nov. 16, 2012.
Claims priority of provisional application 61/684,385, filed on Aug. 17, 2012.
Prior Publication US 2021/0161453 A1, Jun. 3, 2021
Int. Cl. A61B 5/287 (2021.01); A61B 5/283 (2021.01); A61B 5/297 (2021.01); A61B 18/14 (2006.01); A61B 18/18 (2006.01); A61L 29/02 (2006.01); H01R 43/24 (2006.01); H05K 9/00 (2006.01); H05K 13/00 (2006.01); A61B 18/00 (2006.01)

CPC A61B 5/283 (2021.01) [A61B 5/287 (2021.01); A61B 5/297 (2021.01); A61B 18/14 (2013.01); A61B 18/1492 (2013.01); A61B 18/18 (2013.01); A61L 29/02 (2013.01); H01R 43/24 (2013.01); H05K 9/00 (2013.01); H05K 13/00 (2013.01); A61B 2018/00029 (2013.01); A61B 2018/00071 (2013.01); A61B 2018/00083 (2013.01); A61B 2018/00095 (2013.01); A61B 2018/00107 (2013.01); A61B 2018/0016 (2013.01); A61B 2018/00351 (2013.01); A61B 2018/00577 (2013.01); A61B 2018/00642 (2013.01); A61B 2018/00839 (2013.01); A61B 2018/1407 (2013.01); A61B 2018/1435 (2013.01); A61B 2018/1467 (2013.01); A61B 2018/147 (2013.01); A61B 2018/1497 (2013.01); Y10T 29/49176 (2015.01)]

13 Claims

1. A method of mapping and ablating tissue comprising:

providing a device including a distal assembly comprising one or more conductive regions and one or more selectively conductive regions, the one or more conductive regions and one or more selectively conductive regions being in electrical communication with a high-frequency energy source, and the one or more selectively conductive regions being conductive of high-frequency energy and substantially non-conductive of low-frequency electric current;

positioning the distal assembly in contact with an area of target tissue;

recording at least one electrogram from the area of target tissue with the conductive region of the distal assembly;

determining whether the at least one electrogram indicates a presence of an aberrant electrical pathway within the area of target tissue; and

when the presence of an aberrant electrical pathway within the area of target tissue is indicated, transmitting a high-frequency energy to the conductive region and the selectively conductive region, the conductive region and selectively conductive region ablating at least a portion of the area of target tissue.